Physician profile
Ryan John Kennedy
NPI 1700394970
$4,222.57
in general payments reported to CMS, 2019-2025
11 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,131 · 2022: $259 · 2023: $1,106 · 2024: $401 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429 · Travel and Lodging: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.99 |
| Travel and Lodging | $403.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,069.96 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $1,167.98 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $387.51 | 2021-2025 | Azstarys |
| Tris Pharma INC | $187.45 | 2021-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $155.17 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $121.90 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $43.35 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $35.22 | 2021 | |
| Neos Therapeutics, LP | $19.09 | 2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $18.65 | 2023 | Aplenzin |
| Abbvie INC. | $16.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.